Karolinska Development AB ser. B Market Cap ($29.36 Million)
Market Cap & Net Worth: Karolinska Development AB ser. B (KDEV)
Karolinska Development AB ser. B market cap. Karolinska Development AB ser. B (ST:KDEV) has a market capitalization of $29.36 Million (Skr272.85 Million) as of November 4, 2026. Listed on the ST stock exchange, this Sweden-based company holds position #23646 globally and #446 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Karolinska Development AB ser. B's stock price Skr0.29 by its total outstanding shares 942472033 (942.47 Million). Also see KDEV cash flow conversion for how efficiently the company converts equity into cash flow.
Karolinska Development AB ser. B Market Cap History (2015–2026)
Karolinska Development AB ser. B market cap history from 2015 to 2026. Data shows change from $973.68 Million to $29.36 Million (-28.88% CAGR). Check Karolinska Development AB ser. B (KDEV) share price today for real-time trading data and today's change.
Karolinska Development AB ser. B Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Karolinska Development AB ser. B's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore KDEV year-over-year net asset growth to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
4.09x
Karolinska Development AB ser. B's market cap is 4.09 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $608.55 Million | $5.36 Million | -$216.83 Million | 113.54x | N/A |
| 2017 | $583.19 Million | $2.46 Million | $179.59 Million | 236.69x | 3.25x |
| 2018 | $630.86 Million | $3.07 Million | $30.51 Million | 205.29x | 20.68x |
| 2019 | $358.03 Million | $3.38 Million | $657.71 Million | 105.80x | 0.54x |
| 2020 | $182.57 Million | $2.65 Million | -$385.48 Million | 68.87x | N/A |
| 2021 | $539.58 Million | $2.17 Million | $353.85 Million | 248.65x | 1.52x |
| 2022 | $175.47 Million | $2.30 Million | -$145.04 Million | 76.29x | N/A |
| 2023 | $172.22 Million | $2.01 Million | $5.39 Million | 85.51x | 31.98x |
| 2024 | $96.66 Million | $1.84 Million | -$8.10 Million | 52.59x | N/A |
| 2025 | $44.22 Million | $10.80 Million | -$193.85 Million | 4.09x | N/A |
Competitor Companies of KDEV by Market Capitalization
Companies near Karolinska Development AB ser. B in the global market cap rankings as of November 4, 2026. Also see balance sheet size of Karolinska Development AB ser. B for a full breakdown of the balance sheet.
Key companies related to Karolinska Development AB ser. B by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #368 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #414 globally with a market cap of $68.22 Billion USD ( AU$96.41 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $530.76 |
| #368 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $973.36 |
| #414 | CSL Ltd | AU:CSL | $68.22 Billion | AU$198.72 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $228.44 |
Market Capitalization of Karolinska Development AB ser. B (2015–2026)
Market capitalization of Karolinska Development AB ser. B from 2015 to today. Between 2015 and today, Karolinska Development AB ser. B's market cap moved from $973.68 Million to $ 29.36 Million, with a yearly change of -28.88%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Skr29.36 Million | -33.60% |
| 2025 | Skr44.22 Million | -54.25% |
| 2024 | Skr96.66 Million | -43.88% |
| 2023 | Skr172.22 Million | -1.85% |
| 2022 | Skr175.47 Million | -67.48% |
| 2021 | Skr539.58 Million | +195.56% |
| 2020 | Skr182.57 Million | -49.01% |
| 2019 | Skr358.03 Million | -43.25% |
| 2018 | Skr630.86 Million | +8.17% |
| 2017 | Skr583.19 Million | -4.17% |
| 2016 | Skr608.55 Million | -37.50% |
| 2015 | Skr973.68 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of Karolinska Development AB ser. B was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $29.36 Million USD |
| MoneyControl | $29.36 Million USD |
| MarketWatch | $29.36 Million USD |
| marketcap.company | $29.36 Million USD |
| Reuters | $29.36 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Karolinska Development AB ser. B
KDventures AB is a venture capital firm specializing in investments in growth capital, seed stage, and early stage companies. It seeks to invest in pharmaceutical research and development, medical research, medical innovations, healthcare technology, gene research and development, drug delivery technologies, biotechnology, and life science tools and service sectors. The firm seeks to invest in th… Read more